INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
09.10.26 | 15:25
1,310 Euro
+11,97 % +0,140
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,380 | 1,510 | 10.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.09. | Innate Pharma stock maintained at Buy by H.C. Wainwright | 2 | Investing.com | ||
| 18.09. | Innate Pharma Extends Cash Runway Through Q1 2028 As Sobi Partnership Advances Lacutamab Into Phase 3 | 1 | pulse2.com | ||
| 17.09. | Innate Pharma SA H1 Loss Drops | 1 | RTTNews | ||
| 17.09. | Innate Pharma übertrifft Q2-Prognosen, doch die Aktie gibt nach | - | Investing.com Deutsch | ||
| 17.09. | Innate Pharma H1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 17.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.09. | Innate Pharma gives H1 results | 3 | Seeking Alpha | ||
| 17.09. | Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results | 614 | Business Wire | New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 16.09. | Innate Pharma closes Sobi partnership, receives $75m upfront | 2 | Investing.com | ||
| 16.09. | Innate Pharma SA: Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions | 507 | Business Wire | The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD... ► Artikel lesen | |
| 14.09. | Innate Pharma: Fokussierte Pipeline und entscheidende Studiendaten im Blick | 1 | Investing.com Deutsch | ||
| 10.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Innate Pharma SA: Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update | 536 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at... ► Artikel lesen | |
| 02.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.09. | Innate Pharma SA: Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | 488 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 19.08. | Innate Pharma SA - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.08. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast | 592 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00... ► Artikel lesen | |
| 14.08. | Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares | 912 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| 13.08. | Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares | 891 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| 10.08. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,040 | +0,48 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| TME PHARMA | 0,115 | 0,00 % | TME Pharma NV: TME Pharma CEO Message | TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel... ► Artikel lesen | |
| CANSINO BIOLOGICS | 4,160 | +3,48 % | CanSino Biologics Inc: Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New Opportunities | HONG KONG, Aug 27, 2026 - (ACN Newswire) - CanSino Biologics Inc. ('CanSinoBIO,' 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately... ► Artikel lesen | |
| KARYOPHARM | 0,520 | -2,80 % | Karyopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis | - sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested -
NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc.... ► Artikel lesen | |
| ADICET BIO | 5,050 | +1,00 % | H.C. Wainwright raises Adicet Bio stock price target on lupus data | ||
| MEREO BIOPHARMA | 0,316 | +1,94 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights | Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo... ► Artikel lesen | |
| ANNOVIS BIO | 1,028 | -6,03 % | Annovis Bio Inc.: Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease | MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 11,900 | +3,48 % | Integra LifeSciences prices $450M in 9.5% secured notes | ||
| RHYTHM PHARMACEUTICALS | 81,50 | +0,62 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan | -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,360 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,200 | +9,29 % | RECCE PHARMACEUTICALS LTD: Notice of Annual General Meeting/Proxy Form | ||
| MABION | 1,740 | 0,00 % | ODDIFACT: Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia | FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NPOddifact and Mabion aim to bring rituximab's well-established activity in ITP... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +11,97 % bei einem Aktienkurs von 1,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.